We would like to sincerely extend our thoughts and best wishes to all impacted by COVID-19. The safety and health of our employees, external partners and customers is of vital…
CENTERVUE S.p.A. was established in 2008 in Padova. The US subsidiary was opened in 2012.
Today, CENTERVUE is part of Revenio Group. Revenio is one of the leading players in eye diagnostics solutions and ophthalmic products worldwide providing state-of-the-art technology to enable efficient diagnostics of eye diseases. Revenio’s eye related products include CENTERVUE imaging products for the diagnostics and monitoring of the eye as well as Icare tonometers for intraocular pressure measurement (IOP).
Revenio focuses on high-technological diagnostic systems for the early detection and management of sight-threatening pathologies such as Glaucoma, Diabetic Retinopathy and Macular Degeneration.
Imaging products designed and manufactured by CENTERVUE are highly automated, Internet-connected medical devices for the diagnosis and management of ocular pathologies, including those that represent the leading causes of blindness, such as Diabetic Retinopathy, Macular Degenerations and Glaucoma. Icare is the globally leading handheld tonometry brand for Glaucoma diagnosis and management.
Revenio sells its products worldwide in almost 100 countries and has several international patents and patent families. The installed base of the company is more than 7.000 imaging devices and over 80.000 tonometers globally. The company invests approximately 10% annually to R&D. Revenio Group’s management and core team has extensive expertise in the development, marketing and sales of ophthalmic devices.